Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study

Abstract Background Prior studies suggest a link between metabolic dysfunction-associated steatotic liver disease (MASLD) and incident arrhythmias, including atrial fibrillation (AF). However, robust data are lacking from cohorts with liver histology, which remains the gold standard for staging MASL...

Full description

Bibliographic Details
Published in:	Cardiovascular Diabetology
Main Authors:	Tracey G. Simon, Fahim Ebrahimi, Bjorn Roelstraete, Hannes Hagström, Johan Sundström, Jonas F. Ludvigsson
Format:	Article
Language:	English
Published:	BMC 2023-12-01
Subjects:	MASLD Epidemiology Fibrosis Arrhythmia Cardiovascular
Online Access:	https://doi.org/10.1186/s12933-023-02070-5

Similar Items

Readily Available Index of Insulin Sensitivity Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes
by: Stefano Ciardullo, et al.
Published: (2025-06-01)

Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
by: Fares Jamal, et al.
Published: (2025-08-01)

Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease
by: Fenfen Li, et al.
Published: (2025-04-01)

Consensus Statement on Metabolic Dysfunction‐Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL‐TSPGHAN Expert Committee
by: Yu‐Cheng Lin, et al.
Published: (2025-06-01)

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
by: Sanad Dawod, et al.
Published: (2024-11-01)

Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver Disease
by: Sophie Gensluckner, et al.
Published: (2024-02-01)

The Role of Aldosterone and the Mineralocorticoid Receptor in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Mohammed Barigou, et al.
Published: (2025-07-01)

Associations of five dietary indices with metabolic dysfunction-associated steatotic liver disease and liver fibrosis among the United States population
by: Min Xu, et al.
Published: (2024-08-01)

Glycemic variability in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease: a case-control study
by: Yueqiu Wang, et al.
Published: (2025-12-01)

Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents
by: Guang-Xia Shi, et al.
Published: (2024-10-01)

Editorial: Lipid metabolism in metabolic dysfunction- associated steatotic liver disease
by: Sheetalnath Rooge, et al.
Published: (2025-03-01)

Serum Mac-2 binding protein glycosylation isomer as a biomarker for metabolic dysfunction associated steatotic liver disease
by: Ahmed M. F. Mansour, et al.
Published: (2025-05-01)

Microbiota and metabolic dysfunction associated with steatotic liver disease
by: Q. Zhu, et al.
Published: (2024-09-01)

Validation of the American Association for the Study of Liver Disease/European Association for the Study of the Liver Multistep Screening Strategies for Metabolic Dysfunction-associated Steatotic Liver disease
by: Clémence Marie Canivet, et al.
Published: (2025-01-01)

Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease
by: Susana Bernal, et al.
Published: (2025-07-01)

Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study
by: Lian-Zhen Huang, et al.
Published: (2025-01-01)

Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver disease
by: Buket Yigit, et al.
Published: (2025-07-01)

Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases
by: Enrique García-Nieto, et al.
Published: (2024-10-01)

A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease
by: Zülal İstemihan, et al.
Published: (2025-07-01)

Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis
by: Natchaya Polpichai, et al.
Published: (2024-12-01)

Association between Life’s Crucial 9 and metabolic dysfunction-associated steatotic liver disease: the mediating role of neutrophil-percentage-to-albumin ratio
by: Na Zhu, et al.
Published: (2025-06-01)

Association between the lymphocyte-to-high-density lipoprotein ratio and metabolic dysfunction-associated steatotic liver disease among US adults: a cross-sectional study from NHANES 2017 to 2020
by: Chuanzhi Tang, et al.
Published: (2024-12-01)

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
by: Chung-Feng Huang, et al.
Published: (2025-01-01)

Association between trans-palmitoleic acid and metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma: NHANES 1999–2018
by: Qirui Li, et al.
Published: (2025-06-01)

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Ying Wang, et al.
Published: (2025-04-01)

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017–2018 cycle
by: Naim Alkhouri, et al.
Published: (2024-07-01)

Successful Example of Implementing Screening of Liver Fibrosis in Specialist Diabetes Care
by: Muna Tajudin, et al.
Published: (2025-01-01)

Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK biobank
by: Qi Feng, et al.
Published: (2025-07-01)

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
by: Johanna K. DiStefano, et al.
Published: (2025-01-01)

An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease
by: Youngshim Choi, et al.
Published: (2025-06-01)

Impact of genotyping (PTPN2, rs2542151) and (MBOAT7, rs641738) in prediction of fibrosis in Metabolic dysfunction- associated steatotic liver disease’ patients
by: Shimaa Abdelsattar, et al.
Published: (2025-09-01)

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
by: Gina Ryu, et al.
Published: (2025-01-01)

Correction: An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease
by: Youngshim Choi, et al.
Published: (2025-06-01)

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
by: Chung-Feng Huang, et al.
Published: (2024-10-01)

Allyl nonanoate as a novel bile-derived biomarker in metabolic dysfunction-associated steatotic liver disease
by: Soo Hyeon Lee, et al.
Published: (2025-10-01)

Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy
by: Aleksander Jerzy Owczarek, et al.
Published: (2025-02-01)

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
by: Maria Gabriela Fernandes DEZAN, et al.
Published: (2025-09-01)

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
by: Eileen Laurel Yoon, et al.
Published: (2024-10-01)

Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison
by: Zheng Lin, et al.
Published: (2024-05-01)

The Impact of Antidiabetic Therapy on Liver Injury, Steatosis, and Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Oana Albai, et al.
Published: (2025-10-01)